Humoral and cell-mediated immune responses in humans to the NSP4 enterotoxin of rotavirus

Journal of Medical Virology

Volumn 59, Issue 3, 1999, Pages 369-377

  Johansen, Kari ^a,b   Hinkula, Jorma ^b   Espinoza, Felix ^c   Levi, Mikael ^b   Zeng, Carl ^d   Rudén, Ulla ^b   Vesikari, Timo ^e   Estes, Mary ^d   Svensson, Lennart ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c Universidad Nacional Autónoma de Nicaragua León   (Nicaragua)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Enterotoxin; Human; NSP4; Toxic peptide, B and T cell responses

Indexed keywords

ENTEROTOXIN;

ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL PROLIFERATION; CELLULAR IMMUNITY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; PATHOPHYSIOLOGY; PEPTIDE SYNTHESIS; ROTAVIRUS; SEROTYPE; VIRUS DETECTION; VIRUS INFECTION; VIRUS PARTICLE;

ADULT; ANTIBODIES, VIRAL; DNA-DIRECTED RNA POLYMERASES; FINLAND; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFANT; NICARAGUA; RECOMBINANT PROTEINS; ROTAVIRUS; ROTAVIRUS INFECTIONS; SWEDEN; T-LYMPHOCYTES; VIRAL NONSTRUCTURAL PROTEINS;

RNA VIRUSES; ROTAVIRUS;

EID: 0032859762     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199911)59:3<369::AID-JMV18>3.0.CO;2-N     Document Type: Article

References (60)

1. Au KS, Chan WK, Burns JW, Estes MK. 1989. Receptor activity of rotavirus nonstructural glycoprotein NS28. J Virol 63:4553-4562.
2. Ball JM, Tian P, Zeng CQ, Morris AP, Estes MK, 1996. Age-dependent diarrhea induced by a rotaviral nonstructural glycoprotein (see comments). Science 272:101-104.
3. Bernstein DI, Smith VE, Sander DS, Pax KA, Schiff GM, Ward RL. 1990. Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants. J Infect Dis 162:1055-1062.
4. Broliden P, Rudén U, Quattara A, de Thé G, Sölver E, Trojnar J, Wahren B. 1991. Specific synthetic peptides for detection of and discrimination between HIV-1 and HIV-2 infection. J Acquired Immune Defic Syndr 4:952-958.
5. Burns JW, Siadat-Pajouh M, Krishnaney AA, Greenberg HB. 1996. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 272:104-107.
6. Chen SC, Fynan EF, Robinson HL, Lu S, Greenberg HB, Santoro JC, Herrmann JE. 1997. Protective immunity induced by rotavirus DNA vaccines. Vaccine 15:899-902.
7. Chiba S, Yokoyama T, Nakata S, Morita Y, Urasawa T, Taniguchi K, Urasawa S, Nakao T. 1986. Protective effect of naturally acquired homotypic and heterotypic rotavirus antibodies. Lancet 2:417-421.
8. Clark H, Borian F, Bell L, Modesto K, Gouvea V, Plotkin S. 1988. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype l rotavirus season. J Infect Dis 158:570-587.
9. Cong Y, Bowdon H, Elson C. 1996. Identification of an immunodominant T cell epitope on cholera toxin. Eur J Immunol 26:2587-2594.
10. Conner ME, Estes MK, Graham DY. 1988. Rabbit model of rotavirus infection. J Virol 62:1625-1633.
11. Cunliffe NA, Woods PA, Leite JP, Das BK, Ramachandran M, Bhan MK, Hart CA, Glass RI, Gentsch JR. 1997. Sequence analysis of NSP4 gene of human rotavirus allows classification into two main genetic groups. J Med Virol 53:41-50.
12. Deacock S, Schwarer A, Batchelor R, Goldman J, Lechler R. 1992. A rapid limiting dilution assay for measuring frequencies of allore-active, interleukin-2 producing T cells in humans. J Immunol Methods 147:83-92.
13. Diepolder H, Zachoval R, Hoffman R, Wierenga E, Santantonio T, Jung M-C, Eichenlaub D, Pape G. 1995. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346:1006-1007.
14. Dong Y, Zeng C, Ball J, Estes M, Morris A. 1997. The rotavirus enterotoxin NSP4 mobilizes intracellular calcium in human intestinal cells by stimulating phospholipase C-mediated inositol 1,4,5-triphosphate production. Proc Natl Acad Sci USA 94:3960-3965.
15. Franco MA, Greenberg HB. 1995. Role of B cells and cytotoxic T lymphocytes in clearance of and immunity to rotavirus infection in mice. J Virol 69:7800-7806.
16. Franco M, Greenberg H. 1997. Immunity to rotavirus in T cell deficient mice. Virology 238:169-179.
17. Franco MA, Prieto I, Labbe M, Poncet D, Borras-Cuesta F, Cohen J. 1993. An immunodominant cytotoxic T cell epitope on the VP7 rotavirus protein overlaps the H2 signal peptide. J Gen Virol 74: 2579-2586.
18. Franco MA, Lefevre P, Willems P, Tosser G, Lintermanns P, Cohen J. 1994. Identification of cytotoxic T cell epitopes on the VP3 and VP6 rotavirus proteins. J Gen Virol 75:589-596.
19. Gorrell M, Lemm J, Rice C, Griffin D. 1997. Immunization with non-structural proteins promotes functional recovery of alphavirus-infected neurons. J Virol 71:3415-3419.
20. Hall R, Brand T, Lobigs M, MY S, Howard M. 1996. Protective immune responses to the E and NS1 proteins of Murray Valley encephalitis virus in hybrids of flavivirus-resistant mice. J Gen Virol 77:1287-1294.
21. Heath RR, Stagg S, Xu F, McCrae MA. 1997. Mapping of the target antigens of the rotavirus-specific cytotoxic T cell response. J Gen Virol 78:1065-1075.
22. Hinkula J, Svanholm C, Schwartz S, Lundholm P, Brytting M, Engström G, Benthin R, Glaser H, Kohleisen B, Erfle V, Okuda K, Wigzell H, Wahren B. 1997. Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. J Virol 71:5528-5539.
23. Hjelt K, Grauballe PC, Paerregard A, Nielsen OH, Krasilnikoff PA. 1987. Protective effect of preexisting rotavirus specific immuneglobulin A against naturally acquired rotavirus infection in children. J Med Virol 21:39-47.
24. Horie Y, Masamune O, Nakagomi O. 1997. Three major alleles of rotavirus NSP4 proteins identified by sequence analysis. J Gen Virol 78:2341-2346.
25. Ishida SI, Feng N, Gilbert JM, Tang B, Greenberg HB. 1997. Immune responses to individual rotavirus proteins after heterologous and homologous rotavirus infection in mice. J Infect Dis 175:1317-1323.
26. Jacobs S. 1993. A novel recombinant adenovirus vector expressing a flavivirus non-structural protein protects against lethal flavivirus challenge. Clin Sci 85:117-122.
27. Joensuu J, Koskenniemi E, Pang X-L, Vesikari T. 1997. Randomized placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 350:1205-1209.
28. Kapikian AZ, Chanock RM. 1990. Rotaviruses. In: Fields BN, editor. Virology. 2nd ed. New York: Raven Press, p 1353-1404.
29. Kirkwood CD, Palombo EA. 1997. Genetic characterization of the rotavirus nonstructural protein, NSP4. Virology 236:258-265.
30. Kirkwood CD, Coulson BS, Bishop RF. 1996. G3P2 rotaviruses causing diarrhoeal disease in neonates differ in VP4, VP7 and NSP4 sequence from G3P2 strains causing asymptomatic neonatal infection. Arch Virol 141:1661-1676.
31. Mathiesen T, Broliden P-A, Rosen J, Wahren B. 1989. Mapping of IgG subclass and T-cell epitopes on HIV-proteins by synthetic peptides. Immunology 67:453-459.
32. + cell-dependent activities. J Virol 71:8735-8742.
33. Midthun K, Kapikian AZ. 1996. Rotavirus vaccines: an overview. Clin Microbiol Rev 9:423-434.
34. Moore R, Fox B. 1993. Immunization of mice with human immunodeficiency virus glycoprotein gp 160 peptide 315-329 induces both class I and II restricted T-cells: not all T-cells can respond to whole molecule stimulation. AIDS Res Hum Retroviruses 9:51-59.
35. Offit PA. 1996. Host factors associated with protection against rotavirus disease: the skies are clearing. J Infect Dis 174:859-64.
36. Offit P, Cunningham S, Dudzik K. 1991. Memory and distribution of virus-specific cytotoxic T-lymphocytes (CTLs) and CTL precursors after rotavirus infection. J Virol 65:1318-1324.
37. O'Neal CM, Crawford SE, Estes MK, Conner ME. 1997. Rotavirus virus-like particles administered mucosally induce protective immunity. J Virol 71:8707-8717.
38. O'Neal CM, Clements JD, Estes MK, Conner ME. 1998. Rotavirus 2 of 6 viruslike particles administered intranasally with cholera toxin, Escherichia coll heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge. J Virol 72:3390-3393.
39. O'Ryan ML, Matson DO, Estes MK, Pickering LK. 1994. Antirotavirus G type-specific and isotype-specific antibodies in children with natural rotavirus infections. J Infect Dis 169:504-511.
40. Powrie F, Coffman R. 1993. Cytokine regulaton of T-cell function: potential for therapeutic intervention. Immunol Today 14:270-274.
41. Richardsson S, Grimwood K, Bishop R. 1993. Analysis of homotypic and heterotypic serum immune response to rotavirus proteins after primary rotavirus infection by using the radioimmunoprecipitation technique. J Clin Microbiol 31:377-385.
42. + memory T cells to clear rotavirus infection. J Virol 72:726-730.
43. Schlesinger J, Brandriss M, Putnak J, Walsh E. 1990. Cell surface expression of yellow fever virus non-structural glycoprotein NS1: consequences of interaction with antibody. J Gen Virol 71:593-599.
44. Svensson L, Sheshberadaran H, Vene S, Norrby E, Grandien M, Wadell G. 1987a. Serum antibody responses to individual viral polypeptides in human rotavirus infections. J Gen Virol 68:643-651.
45. Svensson L, Sheshberadaran H, Vesikari T, Norrby E, Wadell G. 1987b. Immune response to rotavirus polypeptides after vaccination with heterologous rotavirus vaccines (RIT 4237, RRV-1). J Gen Virol 68:1993-1999.
46. Tian P, Hu Y, Schilling WP, Lindsay DA, Eiden J, Estes MK. 1994. The nonstructural glycoprotein of rotavirus effects intracellular calcium levels. J Virol 68:251-257.
47. 2+ from the endoplasmic reticulum. J Virol 69:5763-5772.
48. Tian P, Ball JM, Zeng CQ, Estes MK. 1996. The rotavirus nonstructural glycoprotein NSP4 possesses membrane destabilization activity. J Virol 70:6973-81.
49. Totterdell B, Banatvala J, Chrystie I, Ball G, Cubitt W. 1988. Systemic lymphoproliferative responses to rotavirus. J Med Virol 25: 37-44.
50. Vesikari T. 1996. Trials of oral bovine and rhesus rotavirus vaccines in Finland: a historical account and present status. Arch Virol Suppl 12:177-186.
51. Vesikari T. 1997. Rotavirus vaccines against diarrhoeal disease. Lancet 350:1538-41.
52. Vesikari T, Isolauri E, Delem A, D'Hondt E, Andre FE, Zissis G. 1983. Immunogenicity and safety of live oral attenuated bovine rotavirus vaccine strain RIT 4237 in adults and young children. Lancet 2:807-811.
53. Wahren B, Rosen J, Sandström E, Mathiesen T, Modrow S, Wigzell H. 1989. HIV-1 peptides induce a proliferative response in lymphocytes from infected persons. J Aquired Immune Defic Syndr 4:448-456.
54. Wahren B, Bratt G, Persson C, Levén B, Hinkula J, Gilljam G, Nordlund S, Eriksson L, Volvovitz F, Broliden P, Sandström E. 1994. Improved cell-mediated immune responses in HIV-1 infected asymptomatic individuals after immunization with envelope glycoprotein gp 160. J Acquired Immune Defic Syndr 7:220-229.
55. Ward RL. 1996. Mechanisms of protection against rotavirus in humans and mice. J Infect Dis 174:851-58.
56. Ward RL, Mason BB, Bernstein DI, Sander DS, Smith VE, Zandle GA, Rappaport RS. 1997. Attenuation of a human rotavirus vaccine candidate did not correlate with mutations in the NSP4 protein gene. J Virol 71:6267-6270.
57. Ward RL, McNeal MM, Sheridan JF. 1992. Evidence that active protection following oral immunization of mice with live rotavirus is not dependent on neutralizing antibody. Virology 188:57-66.
58. Wood D, David T, Chrystie I, Totterdell B. 1988. Chronic enteric virus infection in two T-cell immunodeficient children. J Med Virol 24: 435-444.
59. Zeng C, Wentz M, Cohen J, Estes M, Ramig R. 1996. Characterization and replicase activity of double-layered and single-layered rotavirus-like particles expressed from baculovirus recombinants. J Virol 70:2736-2742.
60. Zhang M, Zeng C, Dong Y, Ball J, Saif L, Morris A, Estes M. 1998. Mutations in rotavirus nonstructural glycoprotein NSP4 are associated with altered virus virulence. J Virol 72:3666-3672.